Objective: The aim of the present study was to explore the role of noradrenaline on the social behaviour of healthy volunteers when they were interacting with a familiar person, their flatmate. Interaction with the flatmate was explored in a cooperative game situation. Methods: Ten pairs of same-sex healthy volunteer flatmates aged 18-25 years were recruited for the experiment. All volunteers gave written informed consent and the study was approved by the institutional ethical committee. A randomised, double blind, placebo-controlled crossover trial of reboxetine versus placebo was conducted. In each of the 10 pairs of volunteers, one (subject) volunteered to take the tablets and the other (flatmate) received no treatment. Reboxetine (4 mg/bd) and placebo were administered orally as identical capsules for 2 weeks. The subjects were randomly assigned to receive either reboxetine or placebo first and there was a two-week washout period following the first treatment. At baseline and the end of each treatment, they filled in the Beck Depression Inventory (BDI), Social Adapation Self-Evaluation Scale (SASS), and Aggression Questionnaire (AQ). Then, they were instructed to play the Tangrams game. This task elicits face-valid social behaviours such as cooperation, giving commands and unilateral grasps. Results: Analysis of covariance showed that there was a statistical trend for reboxetine treatment to increase commands (p=0.055). Conclusion: This study presents preliminary evidence that two weeks' enhancement of noradrenaline transmission induced by reboxetine makes healthy volunteers more self-confident and assertive.
References
1
Abramson LY, Metalsky GI, Alloy LB.
Hopelessness depression: a theory-based subtype of depression.
Psychol Rev.
1989;
96
358-372
4
Bosc M, Dubini A, Polin V.
Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
Eur Neuropsychopharmacol.
1997;
7
((Suppl))
57-70
9
Dubini A, Bosc M, Polin V.
Do noradrenaline and serotonin differentially affect social motivation and behaviour?.
Eur Neuropsychopharmacol.
1997;
7
((Suppl))
49-55
12
Gould GG, Pardon MC, Morilak DA, Frazer A.
Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems.
Neuropsychopharmacol.
2003;
28
1633-1641
13
Keller M.
Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
Gen Hosp Psychiatry.
2001;
23
15-19
14
Knutson B, Wolkowitz WM, Cole SW, Chan T, Moore EA, Johnson RC, Terpstra J, Turner RA, Reus VI.
Selective alteration of personality and social behavior by serotonergic intervention.
Am J Psychiatry.
1998;
155
373-379
15
Libet JM, Lewinsohn PM.
Concept of social skill with special reference to the behavior of depressed persons.
J Consult Clin Psychol.
1973;
40
304-312
19
Stassen HH, Kuny S, Hell D.
The speech analysis approach to determining onset of improvement under antidepressants.
Eur Neuropsychopharmacol.
1998;
8
303-310
25
Versiani M, Amin M, Chouinard G.
Double-blind placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.
J Clin Psychopharmacol.
2000;
20
28-34
